Agomelatine in depressive disorders: Its novel mechanisms of action

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 24, Issue 3, 2012, Pages 290-308

  Srinivasan, Venkataramanujan ^a   Zakaria, Rahimah ^b   Othman, Zahiruddin ^b   Lauterbach, Edward C ^c   Acuña Castroviejo, Darío ^d  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^c MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MONOAMINE OXIDASE A INHIBITOR; PAROXETINE; RAMELTEON; SALBUTAMOL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; VOFOPITANT;

ABDOMINAL PAIN; ANXIETY; ANXIETY DISORDER; ARTICLE; ARTIFICIAL HEART PACEMAKER; BIOSYNTHESIS; BIPOLAR DISORDER; BODY WEIGHT DISORDER; CARDIOTOXICITY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GENERALIZED ANXIETY DISORDER; HORMONE METABOLISM; HUMAN; HYPOTHALAMUS; MAJOR DEPRESSION; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINUS NODE; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS;

EID: 84867492657     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.11090216     Document Type: Article

References (186)

1. Srinivasan V, Smits M, Spence WD, et al: Melatonin in mood disorders. World J Biol Psychiatry 2006; 7:138-151
2. Bunney WE Jr, Murphy DL, Goodwin FK, et al: The switch process from depression to mania: relationship to drugs which alter brain amines. Lancet 1970; 1:1022-1027
3. Sonntag A, Rothe B, Guldner J, et al: Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996; 4:1-13
4. Venkoba Rao A, Parvathi Devi S, Srinivasan V: Urinary melatonin in depression. Int J Psychiatry 1983; 25:167-172
5. Celada P, Puig M, Amargós-Bosch M, et al: The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004; 29:252-265
6. Ohayon MM, Roth T: Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37:9-15
7. Haimov I, Laudon M, Zisapel N, et al: Sleep disorders and melatonin rhythms in elderly people. BMJ 1994; 309:167
8. Rodenbeck A, Huether G, Rüther E, et al: Altered circadian melatonin secretion patterns in relation to sleep in patients with chronic sleep-wake rhythm disorders. J Pineal Res 1998; 25:201-210
9. LegerD, LaudonM, Zisapel N:Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116:91-95
10. Dolberg OT, Hirschmann S, Grunhaus L: Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998; 155:1119-1121
11. Millan MJ, Gobert A, Lejeune E, et al: The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Pharmacol Exp Ther 2003; 306:954-964
12. Bertaina-Anglade V, Mocaer E, Drieu La Rochelle C: Antidepressant-like action of S-20098 (agomelatine) in the learned helplessness test. Int J Neuropsychopharmacol 2002; 5(suppl1):S65
13. Goodwin GM, Emsley R, Rembry S, et al; Agomelatine Study Group: Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry 2009; 70:1128-1137
14. Loo H, Hale A: D' haenen H: Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT (2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Psychopharmacology (Berl) 2002; 17:239-247
15. Kennedy SH, Emsley R: Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16:93-100
16. Pandi-Perumal SR, Srinivasan V, Cardinali DP, et al: Could agomelatine be the ideal antidepressant? Expert Rev Neurother 2006; 6:1595-1608
17. Cardinali DP, Pandi-Perumal SR, Srinivasan V, et al: Therapeutic potential of melatonin agonists. Expert Rev Endocrinol Metab 2008; 3:269-279
18. Klein DC, Weller JL, Moore RY: Melatonin metabolism: neural regulation of pineal serotonin: acetyl coenzyme A Nacetyltransferase activity. Proc Natl Acad Sci USA 1971; 68:3107-3110
19. Cardinali DP, Rosner JM: Metabolism of serotonin by the rat retina in vitro. J Neurochem 1971; 18:1769-1770
20. Bubenik GA: Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47:2336-2348
21. Slominski A, Fischer TW, Zmijewski MA, et al: On the role of melatonin in skin physiology and pathology. Endocrine 2005; 27:137-148
22. Carrillo-Vico A, Calvo JR, Abreu P, et al: Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18:537-539
23. Naranjo MC, Guerrero JM, Rubio A, et al: Melatonin biosynthesis in the thymus of humans and rats. Cell Mol Life Sci 2007; 64:781-790
24. Tricoire H, Møller M, Chemineau P, et al: Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod Suppl 2003; 61:311-321
25. Claustrat B, Brun J, Chazot G: The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9:11-24
26. Hirata F, Hayaishi O, Tokuyama T, et al: In-vitro and in-vivo formation of two new metabolites of melatonin. J Biol Chem 1974; 249:1311-1313
27. Reppert SM, Weaver DR, Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13:1177-1185
28. Reppert SM, Godson C, Mahle CD, et al: Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92:8734-8738
29. Brydon L, Roka F, Petit L, et al: Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 1999; 13:2025-2038
30. Boutin JA, Audinot V, Ferry G, et al: Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005; 26:412-419
31. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al: Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009; 119:821-846
32. Kupfer DJ, Spiker DG, Coble PA, et al: Sleep and treatment prediction in endogenous depression. Am J Psychiatry 1981; 138:429-434
33. Riemann D, Berger M, Voderholzer U: Sleep and depression: a challenge for anti-depresaants, an overview. Biol Psychol 2001; 57:67-103
34. Armitage R: Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl 2007; (433):104-115
35. Ford DE, Kamerow DB: Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989; 262:1479-1484
36. Lam RW: Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006; 21(Suppl 1): S25-S29
37. Lustberg L, Reynolds CF: Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000; 4:253-262
38. Pandi-Perumal SR, Moscovitch A, Srinivasan V, et al: Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Prog Neurobiol 2009; 88:264-271
39. Srinivasan V, Brzezinski A, Spence DW, et al: Sleep, mood disorders and antidepressants: themelatonergic anti-depressant agomelatine offers a new strategy of treatment. Psychiatr Fenn 2010; 41:168-187
40. Kupfer DJ: Depression and associated sleep disturbances: patient's benefits with agomelatine. Eur Neuropsychopharmacol 2006; 16(suppl5): S 639-S643
41. Thase ME: Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006; 8:478-488
42. Ruhé HG, Mason NS, Schene AH: Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007; 12:331-359
43. Rouillon F: Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006; 21(Suppl 1):S31-S35
44. Yous S, Andrieux J, Howell HE, et al: Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992; 35:1484-1486
45. Bogaards JJ, Hissink EM, Briggs M, et al: Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci 2000; 12:117-124
46. Pepin MC, Pothier F, Barden N: Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 1992; 42:991-995
47. Chagraoui A, Protais P, Filloux T, et al: Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl) 2003; 170:17-22
48. Giorgetti M, Tecott LH: Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004; 488:1-9
49. Bourin M, Mocaër E, Porsolt R: Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29:126-133
50. Porsolt RD, Anton G, Blavet N, et al: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47:379-391
51. Barden N, Shink E, Labbe M, et al: Antidepressant action of agomelatine (S20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiat 2005; 29: 08-916
52. Papp M, Gruca P, Boyer PA, et al: Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28:694-703
53. Fuchs E, Simon M, Schmelting B: Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006; 21(Suppl 1):S17-S20
54. Bertaina-Anglade V, la Rochelle CD, Boyer PA, et al: Antidepressant-like effects of agomelatine (S 20098) in the learned helplessnessmodel. Behav Pharmacol 2006; 17:703-713
55. Redman JR, Guardiola-Lemaitre B, Brown M, et al: Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl) 1995; 118:385-390
56. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, et al: Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993; 46:45-49
57. Martinet L, Guardiola-Lemaitre B, Mocaer E: Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996; 54:713-718
58. Redman JR, Francis AJ: Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 1998; 13:39-51
59. Pitrosky B, Kirsch R, Malan A, et al: Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am J Physiol 1999; 277(3 Pt 2): R812-R828
60. Weibel L, Turek FW, Mocaer E, et al: A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000; 880:207-211
61. Leproult R, Van Onderbergen A, L'hermite-Balériaux M, et al: Phase-shifts of 24-hr rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2005; 63:298-304
62. Fuchs E: Social stress in tree shrews as an animal model of depression: an example of a behavioral model of a CNS disorder. CNS Spectr 2005; 10:182-190
63. Loiseau F, Le Bihan C, Hamon M, et al: Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur Neuropsychopharmacol 2006; 16:417-428
64. Rainer Q, Xia L, Guilloux JP, et al: Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 2011; 8:1-15
65. Bannerman DM, Deacon RM, Brady S, et al: A comparison of GluR-A-deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. Behav Neurosci 2004; 118:643-647
66. Fanselow MS, Dong HW: Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010; 65:7-19
67. Lemoine P, Guilleminault C, Alvarez E: Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-1732
68. Kennedy SH, Lam RW, Cohen NL, et al; CANMAT Depression Work Group: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46(Suppl 1):38S-58S
69. Clerc G; Milnacipran/Fluvoxamine Study Group: Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001; 16:145-151
70. Kennedy SH, Rizvi S, Fulton K, et al: A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28:329-333
71. Di Giannantonio M, Di Iorio G, Guglielmo R, et al: Major depressive disorder, anhedonia and agomelatine: an openlabel study. J Biol Regul Homeost Agents 2011; 25:109-114
72. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C: Agomelatine Bipolar Study Group: Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007; 9:628-635
73. Pjrek E, Winkler D, Konstantinidis A, et al: Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2007; 190:575-579
74. Fornaro M, Prestia D, Colicchio S, et al: A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8:287-304
75. Stein DJ, Ahokas AA, de Bodinat C: Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:561-566
76. Tabeeva GR, Sergeev AV, Gromova SA: [Possibilities of preventive treatment of migraine with the MT1-and MT2 agonist and 5-HT2c receptor antagonist agomelatin (valdoxan)]. Zh Nevrol Psikhiatr Im S S Korsakova 2011; 111:32-36
77. Fibrose T, Skwik FI, Schreiner R, et al: Agomelatine improves sleep in patient with Fatal Familial Insomnia. Pharmacopsychiatry 2011; 45(1):34-36
78. Kennedy SH, Rizvi SJ: Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24:479-499
79. Rosen RC, Lane RM, Menza M: Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19:67-85
80. Kennedy SH: Sexual function in remitted depresse patient following agomelatine. Eur Neuropsychopharmacol 2005; 15 (Supp. 3):S440
81. Dubocovitch ML: Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Invest drugs 2006; 7: 670-680
82. Varcoe TJ, Kennaway DJ: Activation of 5-HT2C receptors acutely induces Per1 gene expression in the rat SCN in vitro. Brain Res 2008; 1209:19-28
83. Martin JR, Bös M, Jenck F, et al: 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998; 286:913-924
84. Lader M: Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacol 2007; 17:743-755
85. Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007; 22(Suppl 2):S9-S14
86. Quera-Salva MA, Lemoine P, Guilleminault C: Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 2010; 25:222-229
87. McClung CA: Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007; 114:222-232
88. Guilding C, Piggins HD: Challenging the omnipotence of the suprachiasmatic timekeeper: are circadian oscillators present throughout the mammalian brain? Eur J Neurosci 2007; 25:3195-3216
89. Czeisler CA, Duffy JF, Shanahan TL, et al: Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999; 284:2177-2181
90. Rusak B, Zucker I: Neural regulation of circadian rhythms. Physiol Rev 1979; 59:449-526
91. Akerstedt T: Altered sleep/wake patterns and mental performance. Physiol Behav 2007; 90:209-218
92. Waterhouse J, Minors D, Akerstedt T, et al: Circadian rhythm adjustment: difficulties in assessment caused by masking. Pathol Biol (Paris) 1996; 44:205-207
93. Liu C, Weaver DR, Jin X, et al: Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19:91-102
94. Jin X, von Gall C, Pieschl RL, et al: Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 2003; 23:1054-1060
95. Srinivasan V, Pandi-Perumal SR, Trakht I, et al: Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res 2009; 165:201-214
96. Eser D, Baghai TC, Möller HJ: Evidence of agomelatine's antidepressant efficacy: the key points. Int Clin Psychopharmacol 2007; 22(Suppl 2):S15-S19
97. De Berardis D, Di Iorio G, Acciavatti T, et al: The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10:119-132
98. Llorca PM: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. J Psychopharmacol 2010; 24(Suppl):21-26
99. Srinivasan V, Cardinali DP, Pandi-Perumal SR, et al: Melatonin agonists for treatment of sleep and depressive disorders. J Exptl Integ Med 2011; 1:149-158
100. Kennedy SH, Young AH, Blier P: Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. J Affect Disord 2011; 132(Suppl 1):S21-S28
101. Kennedy SH, Rizvi SJ: Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2009; 14:439-453
102. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, et al: Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9:628-642
103. Banasr M, Soumier A, Hery M, et al: Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006; 59:1087-1096
104. Soumier A, Banasr M, Lortet S, et al: Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009; 34:2390-2403
105. Païzanis E, Renoir T, Lelievre V, et al: Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptorimpaired mice. Int J Neuropsychopharmacol 2010; 13:759-774
106. Moser MB, Moser EI: Functional differentiation in the hippocampus. Hippocampus 1998; 8:608-619
107. Wang JW, David DJ, Monckton JE, et al: Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008; 28:1374-1384
108. Engin E, Treit D: The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 2007; 18:365-374
109. Kasper S, Hajak G, Wulff K, et al: Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71:109-120
110. Kumar A, Singh A: Protective effect of St. John's wort (Hypericum perforatum) extract on 72-hour sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Planta Med 2007; 73:1358-1364
111. Cirelli C, Tononi G: Uncoupling proteins and sleep deprivation. Arch Ital Biol 2004; 142:541-549
112. Cirelli C, Faraguna U, Tononi G: Changes in brain gene expression after long-term sleep deprivation. J Neurochem 2006; 98:1632-1645
113. Szuster-Ciesielska A, Sotwinska M, Stachura A, et al: Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:686-694
114. Andreazza AC, Shao L, Wang JF, et al: Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67:360-368
115. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al: Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16:751-762
116. Maes M, Ruckoanich P, Chang YS, et al: Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:769-783
117. Che Y, Wang JF, Shao L, et al: Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010; 35:296-302
118. Oh DH, Park YC, Kim SH: Increased glycogen synthase kinase-3b mRNA level in the hippocampus of patients with major depression: a study using the stanley neuropathology consortium integrative database. Psychiatry Investig 2010; 7:202-207
119. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al: Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111:135-144
120. Kunz M, Gama CS, Andreazza AC, et al: Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1677-1681
121. Wang JF, Shao L, Sun X, et al: Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11:523-529
122. Clay HB, Sillivan S, Konradi C: Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011; 29:311-324
123. Selek S, Altindag A, Saracoglu G, et al: Prolidase activity and its diagnostic performance in bipolar disorder. J Affect Disord 2011; 129:84-86
124. Ross BM, Maxwell R, Glen I: Increased breath ethane levels in medicated patients with schizophrenia and bipolar disorder are unrelated to erythrocyte omega-3 fatty acid abundance. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:446-453
125. Gigante AD, Young LT, Yatham LN, et al: Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 2011; 14:1075-1089
126. Atmaca M, Tezcan E, Kuloglu M, et al: Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci 2004; 254:231-235
127. Hovatta I, Tennant RS, Helton R, et al: Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 2005; 438:662-666
128. Rammal H, Bouayed J, Younos C, et al: The impact of high anxiety level on the oxidative status of mouse peripheral blood lymphocytes, granulocytes, and monocytes. Eur J Pharmacol 2008; 589:173-175
129. Modica-Napolitano JS, Renshaw PF: Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry 2004; 55:273-277
130. Fattal O, Link J, Quinn K, et al: Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007; 12:429-438
131. Gardner A, Boles RG: Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:730-743
132. Konradi C, Sillivan SE, Clay HB: Mitochondria, oligodendrocytes, and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 2012; 45(1):37-47
133. Kagaya A, Uchitomi Y, Takezaki E, et al: Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan. Neuropsychobiology 1997; 35:128-131
134. Song C, Wang H: Cytokines-mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:760-768
135. Hashioka S: Antidepressants and neuroinflammation: can antidepressants calm glial rage down? Mini Rev Med Chem 2011; 11:555-564
136. Rao JS, Harry GJ, Rapoport SI, et al: Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15:384-392
137. Kim HW, Rapoport SI, Rao JS: Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010; 37:596-603
138. Duncan RE, Bazinet RP: Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder. Curr Opin Clin Nutr Metab Care 2010; 13:130-138
139. Drew JE, Barrett P, Mercer JG, et al: Localization of the melatonin-related receptor in the rodent brain and peripheral tissues. J Neuroendocrinol 2001; 13:453-458
140. Wiechmann AF, Wirsig-Wiechmann CR: Melatonin receptor distribution in the brain and retina of a lizard, Anolis carolinensis. Brain Behav Evol 1994; 43:26-33
141. Stankov B, Cozzi B, Lucini V, et al: Localization and characterization of melatonin binding sites in the brain of the rabbit (Oryctolagus cuniculus) by autoradiography and in vitro ligand-receptor binding. Neurosci Lett 1991; 133:68-72
142. Al-Ghoul WM, Herman MD, Dubocovich ML: Melatonin receptor subtype expression in human cerebellum. Neuroreport 1998; 9:4063-4068
143. Savaskan E, Ayoub MA, Ravid R, et al: Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005; 38:10-16
144. Das A, Belagodu A, Reiter RJ, et al: Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res 2008; 45:117-124
145. Caballero B, Vega-Naredo I, Sierra V, et al: Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescenceaccelerated mice. J Pineal Res 2008; 45:302-311
146. Das A, McDowell M, Pava MJ, et al: The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors. J Pineal Res 2010; 48:157-169
147. Choi SI, Dadakhujaev S, Ryu H, et al: Melatonin protects against oxidative stress in granular corneal dystrophy type 2 corneal fibroblasts by mechanisms that involve membrane melatonin receptors. J Pineal Res 2011; 51:94-103
148. Dhir A, Kulkarni SK: Nitric oxide and major depression. Nitric Oxide 2011; 24:125-131
149. Selek S, Savas HA, Gergerlioglu HS, et al: The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008; 107:89-94
150. Storr M, Koppitz P, Sibaev A, et al: Melatonin reduces nonadrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res 2002; 33: 101-108
151. Castrén E, Rantamäki T: The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010; 70:289-297
152. Hashimoto K: Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64:341-357
153. Yu H, Chen ZY: The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol Sin 2011; 32:3-11
154. Grande I, Fries GR, Kunz M, et al: The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7:243-250
155. Fernandes BS, Gama CS, Ceresér KM, et al: Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45:995-1004
156. Imbesi M, Uz T, Dzitoyeva S, et al: Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells. Neurosci Lett 2008; 439:34-36
157. Molteni R, Calabrese F, Pisoni S, et al: Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010; 11:148-153
158. Peschke E, Mühlbauer E, Musshoff U, et al: Receptor (MT(1) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002; 33:63-71
159. Lerer B, Ebstein RP, Belmaker RH: Subsensitivity of human beta-adrenergic adenylate cyclase after salbutamol treatment of depression. Psychopharmacology (Berl) 1981; 75:169-172
160. Reierson GW, Mastronardi CA, Licinio J, et al: Chronic imipramine downregulates cyclic AMP signaling in rat hippocampus. Neuroreport 2009; 20:307-311
161. Castro LM, Gallant M, Niles LP: Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005; 95:1227-1236
162. Kong X, Li X, Cai Z, et al: Melatonin regulates the viability and differentiation of rat midbrain neural stem cells. Cell Mol Neurobiol 2008; 28:569-579
163. Michel TM, Frangou S, Camara S, et al: Altered glial cell linederived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative post-mortem study. Eur Psychiatry 2008; 23:413-420
164. Wang X, Hou Z, Yuan Y, et al: Association study between plasma GDNF and cognitive function in late-onset depression. J Affect Disord 2011; 132:418-421
165. Di Benedetto B, Kühn R, Nothdurfter C, et al: Ndesalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells:A putative cellularmechanism for quetiapine as antidepressant. Neuropharmacology 2012; 62(1):209-216
166. Niles LP, Armstrong KJ, Rincón Castro LM, et al: Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci 2004; 5:41
167. Willner P: Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res 1983; 287:211-224
168. Dailly E, Chenu F, Renard CE, et al: Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004; 18:601-607
169. Nestler EJ, Carlezon WA Jr: The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59:1151-1159
170. Neumeister A, Willeit M, Praschak-Rieder N, et al: Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 2001; 31:1467-1473
171. Partonen T: Dopamine and circadian rhythms in seasonal affective disorder. Med Hypotheses 1996; 47:191-192
172. Imbesi M, Arslan AD, Yildiz S, et al: The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal 'clock' gene expression in striatal neurons in vitro. J Pineal Res 2009; 46:87-94
173. Gouin JP, Connors J, Kiecolt-Glaser JK, et al: Altered expression of circadian rhythm genes among individuals with a history of depression. J Affect Disord 2010; 126:161-166
174. Soria V, Martínez-Amorós E, Escaramís G, et al: Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010; 35:1279-1289
175. Benedetti F, Dallaspezia S, Fulgosi MC, et al: Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:631-635
176. Benedetti F, Serretti A, Colombo C, et al: Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2003; 123B:23-26
177. Partonen T, Treutlein J, Alpman A, et al: Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med 2007; 39:229-238
178. Johansson C, Willeit M, Smedh C, et al: Circadian clockrelated polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 2003; 28:734-739
179. Tunstall RR, Shukla P, Grazul-Bilska A, et al: MT2 receptors mediate the inhibitory effects of melatonin on nitric oxideinduced relaxation of porcine isolated coronary arteries. J Pharmacol Exp Ther 2011; 336:127-133
180. Cabrera J, Quintana J, Reiter RJ, et al: Melatonin prevents apoptosis and enhances HSP27 mRNA expression induced by heat shock in HL-60 cells: possible involvement of the MT2 receptor. J Pineal Res 2003; 35:231-238
181. Ivanova SA, Semke VY, Vetlugina TP, et al: Signs of apoptosis of immunocompetent cells in patients with depression. Neurosci Behav Physiol 2007; 37:527-530
182. McKernan DP, Dinan TG, Cryan JF: "Killing the Blues": a role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol 2009; 88:246-263
183. Venegas C, García JA, Escames G, et al: Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2011; 52:217-227
184. Demyttenaere K: Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011; 21(Suppl 4):S703-S709
185. Pjrek E, Winkler D, Konstantinidis A, et al: Agomelatine in the treatment of seasonal disorder. Psychopharmacology (Berl) 2007; 190(4):575-579
186. Olié JP, Kasper S: Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10(5): 661-673